XML 21 R6.htm IDEA: XBRL DOCUMENT v3.19.1
Consolidated Statements of Stockholders' Equity - USD ($)
Total
Preferred stock
Common stock
Additional paid-in capital
Accumulated deficit
Accumulated other comprehensive income (loss)
Non- controlling interest
Beginning balance (shares) at Dec. 31, 2015   23 72,217,965        
Beginning balance at Dec. 31, 2015 $ 175,933,053 $ 0 $ 72,218 $ 534,004,564 $ (361,097,896) $ 2,708,339 $ 245,828
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Issuance of common stock for cash, net of financing costs (shares)     658,748        
Issuance of common stock for cash, net of financing costs 6,295,761   $ 659 6,295,102      
Issuance of common stock for Bioject acquisition (shares)     440,122        
Issuance of common stock for Bioject acquisition 4,300,000   $ 440 4,299,560      
Payment to minority stockholders (149,559)           (149,559)
Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (shares)     450,045        
Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments 1,640,740   $ 449 1,640,291      
Cashless exercise of stock options and warrants (shares)     295,490        
Cashless exercise of stock options and warrants 0   $ 296 (296)      
Stock-based compensation 10,479,135     10,479,135      
Net loss attributable to common stockholders (73,740,339)       (73,740,339)    
Unrealized gain (loss) on short-term investments, net of tax (111,967)         (111,967)  
Unrealized loss on investment in affiliated entity, net of tax (1,268,404)         (1,268,404)  
Ending balance (shares) at Dec. 31, 2016   23 74,062,370        
Ending balance at Dec. 31, 2016 123,378,420 $ 0 $ 74,062 556,718,356 (434,838,235) 1,327,968 96,269
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Issuance of common stock for cash, net of financing costs (shares)     15,437,406        
Issuance of common stock for cash, net of financing costs 94,347,922   $ 15,437 94,332,485      
Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (shares)     857,868        
Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments 1,342,250   $ 859 1,341,391      
Stock-based compensation 13,070,962     13,070,962      
Net loss attributable to common stockholders (88,205,772)       (88,205,772)    
Unrealized gain (loss) on short-term investments, net of tax 7,458         7,458  
Unrealized loss on investment in affiliated entity, net of tax (1,452,431)         (1,452,431)  
Ending balance (shares) at Dec. 31, 2017   23 90,357,644        
Ending balance at Dec. 31, 2017 142,488,809 $ 0 $ 90,358 665,775,504 (523,356,317) (117,005) 96,269
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Issuance of common stock for cash, net of financing costs (shares)     5,669,025        
Issuance of common stock for cash, net of financing costs 29,227,776   $ 5,669 29,222,107      
Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (shares)     1,199,141        
Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments 1,809,526   $ 1,199 1,808,327      
Stock-based compensation 10,654,622     10,988,277 (333,655)    
Net loss attributable to common stockholders (96,967,830)       (96,967,830)    
Unrealized gain (loss) on short-term investments, net of tax (180,496)         (180,496)  
Unrealized loss on investment in affiliated entity, net of tax 0            
Ending balance (shares) at Dec. 31, 2018   23 97,225,810        
Ending balance at Dec. 31, 2018 $ 87,032,407 $ 0 $ 97,226 $ 707,794,215 $ (620,426,436) $ (528,867) $ 96,269